Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease

Diabetes Care

Volumn 27, Issue 8, 2004, Pages 1929-1935

  Magnusson, Martin ^a   Melander, Olle ^a   Israelsson, Bo ^a   Grubb, Anders ^b   Groop, Leif ^a   Jovinge, Stefan ^a,b,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Lund Strategic Research Center   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; CYSTATIN C; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ENZYME IMMUNOASSAY; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROTEIN DETERMINATION; SCREENING TEST; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FINLAND; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; REFERENCE VALUES; SWEDEN;

EID: 3343015514     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.8.1929     Document Type: Article

References (43)

1. Rydèn L, Malmberg K: Reducing the impact of the diabetics heart's increased vulnerability to cardiovascular disease. Dial Cardiovasc Med 5:5-20, 2000
2. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431, 1998
3. Steiner G: Diabetes and atherosclerosis: an overview. Diabetes 30:1-7, 1981
4. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 214:2035-2038, 1979
5. Butler R, MacDonald TM, Struthers AD, Morris AD: The clinical implications of diabetic heart disease. Eur Heart J 19:1617-1627, 1998
6. Vanninen E, Mustonen J, Vainio P, Lansimies E, Uusitupa M: Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Cardiol 70:371-378, 1992
7. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, Kitzman DW, Hopkins PN, Morgan D, Rao DC, Devereux RB: Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation 103:102-107, 2001
8. Grossman E, Shemesh J, Shamiss A, Thaler M, Caroll J, Rosenthal T: Left Ventricular mass in diabetes-hypertension. Arch Intern Med 152:1001-1004, 1992
9. Vakili BA, Okin PM, Devereux RB: Prognostic implications of left ventricular hypertrophy. Am Heart J 141:334-341, 2001
10. Tateyama H, Hino J, Minamino N, Kangawa K, Ogihara T, Matsuo H: Characterization of immunoreactive brain natriuretic peptide in human cardiac atrium. Biochem Biophys Res Commun 166:1080-1087, 1990
11. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA: Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 76:832-838, 1993
12. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, et al: Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87:1402-1412, 1991
13. Tateyama H, Hino J, Minamino N, Kangawa, Minamino T, Sakai K, Ogihara T, Matsuo H: Concentrations and molecular forms of brain natriuretic peptide in plasma. Biochem Biophys Res Commun 185:760-767, 1992
14. Hino J, Tateyama H, Minamino N, Kangawa K, Matsuo H: Isolation and identification of human brain natriuretic peptides in cardiac atrium. Biochem Biophys Res Commun 167:693-700, 1990
15. Kambayashi Y, Nakao K, Mukoyama M, Saito Y, Ogawa Y, Shiono S, Inouye K, Yoshida N, Imura H: Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett 259:341-345, 1990
16. Omland T, Aakvaag A, Vik-Mo H: Plama cardiac natriuretic peptide determination as ascreening test for the detection of patients with mild left ventricular impairment. Heart 76:232-237, 1996
17. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, Drennan C, Richards M, Turner J, Yandle T: Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 343:440-444, 1994
18. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J: Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 310:193-197, 2001
19. Johnstone D, Limacher M, Rousseau M, Liang CS, Ekelund L, Herman M, Stewart D, Guillotte M, Bjerken G, Gaasch W, et al.: Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). Am J Cardiol 70:894-900, 1992
20. Groop L, Forsblom C, Lehtovirta M, Tuomi T, Karanko S, Nissen M, Ehrnstrom BO, Forsen B, Isomaa B, Snickars B, Taskinen MR: Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 45:1585-1593, 1996
21. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727), p. 1-113.
22. Hughes D, Talwar S, Squire IB, Davies JE, Ng LL: An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci (Lond) 96:373-380, 1999
23. Mussap M, Ruzzante N, Varagnolo M, Plebani M: Quantitative automated particle-enhanced immunonephelometric assay for the routinary measurment of human cystatin C. Clin Chem Lab Med 36:859-865, 1998
24. Khyse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindstrom V, Grubb A: Serum cystatin C, determined by a rapid, automated particle-enhanced turbiditmetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 40:1921-1926, 1994
25. Yu CM, Sanderson JE, Shum IO, Chan S, Yeung LY, Hung YT, Cockram CS, Woo KS: Diastolic dysfunction and natriuretic peptides in systolic heart failure: higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 17:1694-1702, 1996
26. Yano Y, Katsuki A, Gabazza EC, Ito K, Fujii M, Furuta M, Tuchihashi K, Goto H, Nakatani K, Hori Y, Sumida Y, Adachi Y: Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbumineria. J Clin Endocrinol Metab 84:2353-2356, 1999
27. Mosterd A, Hoes A, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE: Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 20:447-455, 1999
28. Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer S, Doring A, Broeckel U, Riegger G, Schunkert H: Prevalence of left ventricular diastotic dysfunction in the community: results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 24:320-328, 2003
29. Langenickel T, Pagel I, Hohnel K, Dietz R, Willenbrock R: Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am J Physiol Heart Circ Physiol 278:H1500-H1506, 2000
30. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA: The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in the human plasma. Biochem Biophys Res Commun 214:1175-1183, 2000
31. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA: Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 47:287-296, 1997
32. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97:1921-1929, 1998
33. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction: Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 37:1781-1787, 2001
34. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic pepticle (N-BNP) concentrations. Lancet 355:1126-1130, 2000
35. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M, Giannessi D: The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 40:371-377, 2002
36. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, Schenk J: Development of a novel, N-terminal-proBNP (NT-proBNP) assay with low detection limit. Scand J Clin Lab Invest Suppl 230:177-181, 1999
37. Taegtmeyer H, McNulty P, Young ME: Adaption and maladaption of the heart in diabetes. Part I. General concepts. Circulation 105:1727-1733, 2002
38. Young ME, McNulty P, Taegtmeyer H: Adaption and maladaption of the heart in diabetes. Part II. Potential mechanisms. Circulation 105:1861-1870, 2002
39. Braunwald E, Bristow MR: Congestive heart failure: fifty years of progress. Circulation 102:IV14-IV23, 2000
40. King LM, Opie LH: Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with a residual flow. Cardiovasc Res 39:381-392, 1998
41. McCullough PA, Omland T, Maisel AS: B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 4:72-80, 2003 0
42. Rakowski H, Appleton C, Chan KL, Dumesnil JG, Honos G, Jue J, Koilpillai C, Lepage S, Martin RP, Mercier LA, O'Kelly B, Prieur T, Sanfilippo A, Sasson Z, Alvarez N, Pruitt R, Thompson C, Tomlinson C: Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr 9:736-760, 1996
43. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzym inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002